{"schemaVersion":1,"research":true,"symbol":"unh","name":"Unitedhealth Group","topic":"moat","path":"/stock/unh/moat","status":"published","version":11,"updatedAt":"2026-10-20T01:31:20.276Z","locked":false,"publicFairValue":false,"fairValue":null,"moat":{"verdict":"narrow","summary":"A qualified narrow moat rests on Optum Insight’s multiyear services and integration into customers’ technology applications, supporting switching friction. Network breadth establishes scale but does not demonstrate superior costs or network effects. Repricing and earnings recovery continued through September 2026, while employer attrition, pharmacy volume declines and insufficient local care density demonstrate erosion. Pricing power remains constrained and mixed.","advantages":[{"mechanism":"switching_costs","claim":"Optum Insight’s multiyear delivery arrangements and integrations with other vendors’ applications support a current, bounded switching-cost advantage. Replacement can require changes to connected systems and ongoing service arrangements; actual migration costs are not quantified.","durability":"Several-year delivery periods support persistence, but exceptional durability is unproven. Backlog includes anticipated renewals and affiliated agreements, limiting its value as evidence of external customer commitment.","risks":"Backlog declined between year-end 2024 and 2025. Technology replacement, failed implementations and competitive alternatives could weaken integration-based dependency. Third-quarter revenue growth does not establish external renewal strength.","invalidation":"The thesis would fail if external customers routinely replaced integrated products without material disruption, or sustained external contract losses and declining binding obligations demonstrated that integrations no longer supported repeat demand. Further backlog declines would be a warning, requiring separation of affiliated business and anticipated renewals.","competitors":[],"evidenceIds":["e107","e112","e197"],"counterEvidenceIds":["e108","e109","e110","e111","e124"]}],"evidence":[{"id":"e1","location":"2025 Form 10-K, subsidiary capital infusions net of dividends","sourceId":"filing-1","excerpt":"For the year ended December 31, 2025, the Company’s domestic insurance and HMO subsidiaries received capital infusions from its parent companies, net of dividends, of $535 million."},{"id":"e4","location":"2025 Form 10-K, aggregate statutory capital and surplus","sourceId":"filing-1","excerpt":"The Company's financially regulated subsidiaries had estimated aggregate statutory capital and surplus of $43.1 billion as of December 31, 2025."},{"id":"e5","location":"2025 Form 10-K, statutory capital and surplus necessary to satisfy regulatory requirements","sourceId":"filing-1","excerpt":"The estimated statutory capital and surplus necessary to satisfy regulatory requirements of the Company's financially regulated subsidiaries was approximately $23.2 billion as of December 31, 2025."},{"id":"e22","location":"2025 Form 10-K, share-based compensation expense and unrecognized compensation","sourceId":"filing-1","excerpt":"(in millions, except per share amounts)\nFor the Years Ended December 31,\n2025\n2024\n2023\nStock Options\nWeighted-average grant date fair value of shares granted, per share\n$\n110 \n$\n138 \n$\n134 \nTotal intrinsic value of stock options exercised\n616 \n1,886 \n1,325 \nRestricted Shares\nWeighted-average grant date fair value of shares granted, per share\n421 \n523 \n493 \nTotal fair value of restricted shares vested\n553 \n690 \n803 \nEmployee Stock Purchase Plan\nNumber of shares purchased\n1 \n1 \n1 \nShare-Based Compensation Items\nShare-based compensation expense, before tax\n$\n971 \n$\n1,018 \n$\n1,059 \nShare-based compensation expense, net of tax effects\n865 \n896 \n937 \nIncome tax benefit realized from share-based award exercises\n130 \n216 \n231 \n(in millions, except years)\nDecember 31, 2025\nUnrecognized compensation expense related to share awards\n$\n1,333 \nWeighted-average years to recognize compensation expense\n1.3\nShare-Based Compensation Recognition and Estimates"},{"id":"e39","location":"2025 Form 10-K, CMS premium revenue concentration","sourceId":"filing-1","excerpt":"As a percentage of the Company’s total consolidated revenues, premium revenues from CMS were 44%, 40% and 40% for the years ended December 31, 2025, 2024 and 2023, respectively, most of which were generated by UnitedHealthcare Medicare & Retirement and included in the UnitedHealthcare segment."},{"id":"e49","location":"2025 Form 10-K, available-for-sale debt securities in unrealized loss positions","sourceId":"filing-1","excerpt":"agency mortgage-backed securities\n416 \n(5)\n1,863 \n(170)\n2,279 \n(175)\nTotal debt securities - available-for-sale\n$\n16,677 \n$\n(518)\n$\n24,223 \n$\n(2,440)\n$\n40,900 \n$\n(2,958)\nThe Company’s unrealized losses from all securities as of December 31, 2025 were generated from approximately 24,000 positions out of a total of 41,000 positions."},{"id":"e51","location":"2025 Form 10-K, management explanation of investment unrealized losses","sourceId":"filing-1","excerpt":"The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectibility of principal and interest."},{"id":"e56","location":"2025 Form 10-K, available-for-sale debt credit-loss allowance","sourceId":"filing-1","excerpt":"The allowance for credit losses on available-for-sale debt securities as of December 31, 2025 and 2024 was not material."},{"id":"e107","location":"2025 Form 10-K, Optum Insight extended delivery periods","sourceId":"filing-1","excerpt":"Many of Optum Insight’s software and information products and professional services are delivered over extended periods, often several years."},{"id":"e108","location":"2025 Form 10-K, Optum Insight backlog definition","sourceId":"filing-1","excerpt":"The backlog consists of estimated revenue from signed contracts, other legally binding agreements and anticipated contract renewals based on historical experience with Optum Insight’s customers."},{"id":"e109","location":"2025 Form 10-K, December 2025 Optum Insight backlog","sourceId":"filing-1","excerpt":"Optum Insight’s aggregate backlog as of December 31, 2025 was approximately $31.1 billion, of which $18.3 billion is expected to be realized within the next 12 months."},{"id":"e110","location":"2025 Form 10-K, affiliated agreements within backlog","sourceId":"filing-1","excerpt":"The aggregate backlog includes $12.9 billion related to affiliated agreements."},{"id":"e111","location":"2025 Form 10-K, December 2024 comparative backlog","sourceId":"filing-1","excerpt":"Optum Insight’s aggregate backlog as of December 31, 2024, was $32.8 billion, including $12.5 billion related to affiliated agreements."},{"id":"e112","location":"2025 Form 10-K, Optum Insight vendor integrations","sourceId":"filing-1","excerpt":"Optum Insight’s products are also supported and distributed through an array of alliances and business partnerships with other technology vendors, who integrate and interface Optum Insight’s products with their applications."},{"id":"e113","location":"2025 Form 10-K, Optum Rx pharmacy network","sourceId":"filing-1","excerpt":"Optum Rx Optum Rx provides a full spectrum of pharmacy care services through its network of approximately 64,000 retail pharmacies, through home delivery, specialty and community health pharmacies, the provision of in-home and community-based infusion services and through rare disease and gene therapy support services."},{"id":"e114","location":"2025 Form 10-K, discounted provider access and Optum capabilities","sourceId":"filing-1","excerpt":"UnitedHealthcare arranges for discounted access to care through its extensive networks and uses Optum’s capabilities to help coordinate and provide patient care, improve affordability of medical care, analyze cost trends, manage pharmacy care services, work with care providers more effectively and create a simpler and more satisfying consumer and physician experience."},{"id":"e115","location":"2025 Form 10-K, fixed annual risk-based premium arrangements","sourceId":"filing-1","excerpt":"UnitedHealthcare Employer & Individual offers risk-based products under which it assumes responsibility for medical and administrative costs in exchange for a monthly premium, typically a fixed rate per individual served for a one-year period."},{"id":"e116","location":"2025 Form 10-K, realized pricing and medical-cost assumption shortfall","sourceId":"filing-1","excerpt":"For 2025, our pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred, significantly impacting our earnings."},{"id":"e117","location":"2025 Form 10-K, consolidated and segment operating results","sourceId":"filing-1","excerpt":"2024 Revenues UnitedHealthcare $ 344,903 $ 298,208 $ 281,360 $ 46,695 16 % Optum Health 101,957 105,358 95,319 (3,401) (3) Optum Insight 19,417 18,757 18,932 660 4 Optum Rx 154,726 133,231 116,087 21,495 16 Optum eliminations (5,480) (4,389) (3,703) (1,091) 25 Optum 270,620 252,957 226,635 17,663 7 Eliminations (167,956) (150,887) (136,373) (17,069) 11 Consolidated revenues $ 447,567 $ 400,278 $ 371,622 $ 47,289 12 % Earnings from operations UnitedHealthcare $ 9,425 $ 15,584 $ 16,415 $ (6,159) (40) % Optum Health (278) 7,770 6,560 (8,048) (104) Optum Insight 2,624 3,097 4,268 (473) (15) Optum Rx 7,193 5,836 5,115 1,357 23 Optum 9,539 16,703 15,943 (7,164) (43) Consolidated earnings from operations $ 18,964 $ 32,287 $ 32,358 $ (13,323) (41) % Operating margin UnitedHealthcare 2.7 % 5.2 % 5.8 % (2.5) % Optum Health (0.3) 7.4 6.9 (7.7) Optum Insight 13.5 16.5 22.5 (3.0) Optum Rx 4.6 4.4 4.4 0.2 Optum 3.5 6.6 7.0 (3.1) Consolidated operating margin 4.2 % 8.1 % 8.7 % (3.9) % 29 Table of Contents UnitedHealthcare The following table summarizes UnitedHealthcare revenues by business: For the Years Ended December 31, Change (in millions, except percentages) 2025 2024 2023 2025 vs."},{"id":"e122","location":"2025 Form 10-K, regulated subsidiary dividend restrictions","sourceId":"filing-1","excerpt":"These laws and regulations may restrict the ability of our regulated subsidiaries to pay dividends to our holding companies."},{"id":"e123","location":"2025 Form 10-K, generic competitor categories","sourceId":"filing-1","excerpt":"Our competitors include organizations ranging from startups to highly sophisticated Fortune 50 global enterprises, for-profit and non-profit companies, and private and government-sponsored entities."},{"id":"e124","location":"2025 Form 10-K, technology development and maintenance requirements","sourceId":"filing-1","excerpt":"Our ability to protect and enhance existing systems and develop new systems to keep pace with changes in information processing technology (including AI), regulatory standards and changing customer preferences will require our ongoing commitment of significant development and operational resources."},{"id":"e127","location":"2025 Form 10-K, medical claims settlement timing","sourceId":"filing-1","excerpt":"Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service."},{"id":"e128","location":"2025 Form 10-K, auditor opinion on internal control","sourceId":"filing-1","excerpt":"We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 2, 2026, expressed an unqualified opinion on the Company's internal control over financial reporting."},{"id":"e130","location":"June 2026 Form 10-Q, earnings, medical care ratio and return on equity","sourceId":"filing-2","excerpt":"(4)\n2,069 \n2,145 \n(76)\n(4)\nTotal operating costs\n104,041 \n106,466 \n(2,425)\n(2)\n206,772 \n206,922 \n(150)\n— \nEarnings from operations\n7,991 \n5,150 \n2,841 \n55 \n16,981 \n14,269 \n2,712 \n19 \nInterest expense\n(962)\n(1,027)\n65 \n(6)\n(1,917)\n(2,025)\n108 \n(5)\nLoss on sale of subsidiary and subsidiaries held for sale\n(61)\n(41)\n(20)\n49 \n(133)\n(56)\n(77)\n138 \nEarnings before income taxes\n6,968 \n4,082 \n2,886 \n71 \n14,931 \n12,188 \n2,743 \n23 \nProvision for income taxes\n(1,298)\n(510)\n(788)\n155 \n(2,780)\n(2,142)\n(638)\n30 \nNet earnings\n5,670 \n3,572 \n2,098 \n59 \n12,151 \n10,046 \n2,105 \n21 \nEarnings attributable to noncontrolling interests\n(186)\n(166)\n(20)\n12 \n(387)\n(348)\n(39)\n11 \nNet earnings attributable to UnitedHealth Group common shareholders\n$\n5,484 \n$\n3,406 \n$\n2,078 \n61 \n%\n$\n11,764 \n$\n9,698 \n$\n2,066 \n21 \n%\nDiluted earnings per share attributable to UnitedHealth Group common shareholders \n$\n6.04 \n$\n3.74 \n$\n2.30 \n$\n12.94 \n$\n10.61 \n$\n2.33 \nMedical care ratio (a)\n86.7 \n%\n89.4 \n%\n(2.7)\n%\n85.3 \n%\n87.1 \n%\n(1.8)\n%\nOperating cost ratio\n12.7 \n12.3 \n0.4 \n13.3 \n12.4 \n0.9 \nOperating margin\n7.1 \n4.6 \n2.5 \n7.6 \n6.5 \n1.1 \nTax rate\n18.6 \n12.5 \n6.1 \n18.6 \n17.6 \n1.0 \nNet earnings margin (b)\n4.9 \n3.1 \n1.8 \n5.3 \n4.4 \n0.9 \nReturn on equity (c)\n22.3 \n%\n14.4 \n%\n7.9 \n24.3 \n%\n20.6 \n%\n3.7 \n(a)Medical care ratio (MCR) is calculated as medical costs divided by premium revenue."},{"id":"e132","location":"June 2026 Form 10-Q, annualized consolidated return-on-equity definition","sourceId":"filing-2","excerpt":"(c)Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity."},{"id":"e134","location":"June 2026 Form 10-Q, pricing and volume drivers of revenue","sourceId":"filing-2","excerpt":"18\nTable of Contents\n2026 RESULTS OF OPERATIONS COMPARED TO 2025 RESULTS OF OPERATIONS\nConsolidated Financial Results\nRevenues\nThe increases in revenues were primarily driven by pricing trends at UnitedHealthcare, partially offset by decreased people served through Medicare Advantage, commercial risk-based offerings and Medicaid and a decrease in patients served under value-based arrangements at Optum Health."},{"id":"e136","location":"June 2026 Form 10-Q, reserve development, cost management and pricing effects on MCR","sourceId":"filing-2","excerpt":"The MCR decreased due to favorable prior period reserve development, affordability and medical cost management initiatives, and pricing trends, partially offset by medical costs trend which remains above historical levels and continues to be affected by higher provider reimbursement under the No Surprises Act and increased service and coding intensity in commercial."},{"id":"e154","location":"June 2026 Form 10-Q, disclosed credit ratings and outlooks","sourceId":"filing-2","excerpt":"Best\nRatings\nOutlook\nRatings\nOutlook\nRatings\nOutlook\nRatings\nOutlook\nSenior unsecured debt\nA2\nNegative\nA+\nNegative\nA\nNegative\nA-\nStable\nCommercial paper\nP-1\nn/a\nA-1\nn/a\nF1\nn/a\nAMB-1\nn/a\nThe availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions."},{"id":"e158","location":"June 2026 Form 10-Q, deposit accounting for risk-limiting agreements","sourceId":"filing-2","excerpt":"These agreements do not qualify for reinsurance accounting and are therefore accounted for under deposit accounting."},{"id":"e159","location":"June 2026 Form 10-Q, repurchased shares and forward repurchase settlement","sourceId":"filing-2","excerpt":"Share Repurchase Program. During the six months ended June 30, 2026, we repurchased approximately 10.5 million shares at an average price of $344.08 per share, including 6.4 million shares purchased and held by a counterparty at an average price of $312.73 per share pursuant to forward share repurchase contracts that were settled on July 1, 2026."},{"id":"e166","location":"June 2026 Form 10-Q, July acquisition consideration and deferred payment","sourceId":"filing-2","excerpt":"On July 2, 2026, we completed the acquisition for $1.5 billion in cash, with the remaining $1.5 billion payable within one year."},{"id":"e183","location":"June 2026 Form 10-Q, available benefit, network and premium adjustments","sourceId":"filing-2","excerpt":"For example, we can seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the \n17\nTable of Contents\nmember premiums supplementing the monthly payments we receive from the government."},{"id":"e197","location":"June 2026 Form 10-Q, remaining products-and-services performance obligations and exclusions","sourceId":"filing-2","excerpt":"As of June 30, 2026, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $10.7 billion, of which more than half is expected to be recognized in the next three years."},{"id":"e205","location":"June 2026 Form 10-Q, realized Medicare Advantage contraction following benefit and pricing actions","sourceId":"filing-2","excerpt":"Continued funding pressures have resulted in benefit and pricing actions, causing contraction in our Medicare Advantage membership, which we expect to continue throughout 2026."},{"id":"e216","location":"June 2026 Form 10-Q, bank credit facility covenant compliance","sourceId":"filing-2","excerpt":"As of June 30, 2026, we were in compliance with the various covenants under our bank credit facilities."},{"id":"e223","location":"June 2026 Form 10-Q, July payment of forward repurchase liability","sourceId":"filing-2","excerpt":"As of June 30, 2026, the Company had a liability of $2.0 billion related to the settlement of the forward contracts, which was paid on July 1, 2026."},{"id":"e225","location":"June 2026 Form 10-Q, competitive and regulatory pricing considerations","sourceId":"filing-2","excerpt":"We continually evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments."},{"id":"e226","location":"June 2026 Form 10-Q, voluntary individual exchange profit rebate pledge","sourceId":"filing-2","excerpt":"Additionally, we have voluntarily pledged to rebate 2026 profits on our individual exchange products to customers as policymakers continue to work to determine how to improve affordability in this marketplace."},{"id":"e234","location":"June 2026 Form 10-Q, membership by funding arrangement and revenue drivers","sourceId":"filing-2","excerpt":"2025 Commercial: Risk-based 7,655 8,440 (785) (9) % Fee-based 22,265 21,530 735 3 Total Commercial 29,920 29,970 (50) — Medicare Advantage 7,565 8,350 (785) (9) Medicaid 6,780 7,490 (710) (9) Medicare Supplement (Standardized) 4,260 4,305 (45) (1) Total Community and Senior 18,605 20,145 (1,540) (8) Total UnitedHealthcare - Medical 48,525 50,115 (1,590) (3) % Supplemental Data: Medicare Part D stand-alone 2,710 2,800 (90) (3) % South American businesses held for sale 1,145 1,165 (20) (2) % For the three months ended June 30, 2026, UnitedHealthcare’s revenues decreased due to the contraction in people served through Medicare Advantage, risk-based commercial offerings and Medicaid offerings; and our pledge to rebate profits on our individual exchange products to customers; partially offset by pricing trends and actions, including increased Medicaid rates, and growth in people served through fee-based commercial offerings."},{"id":"e236","location":"June 2026 Form 10-Q, cash sources, uses and operating cash-flow timing benefits","sourceId":"filing-2","excerpt":"2025 Sources of cash: Cash provided by operating activities $ 19,964 $ 12,644 $ 7,320 Issuances of short-term borrowings and long-term debt, net of repayments — 1,566 (1,566) Cash received from dispositions and other strategic transactions, net 1,091 109 982 Proceeds from common stock issuances 359 581 (222) Sales and maturities of investments, net of purchases — 1,327 (1,327) Repayments of care provider loans - cyberattack 197 1,293 (1,096) Customer funds administered 332 — 332 Other 199 — 199 Total sources of cash 22,142 17,520 4,622 Uses of cash: Cash dividends paid (4,092) (3,912) (180) Common stock repurchases (1,646) (5,545) 3,899 Repayments of short-term borrowings and long-term debt, net of issuances (4,813) — (4,813) Cash paid for acquisitions and other transactions, net of cash assumed (98) (734) 636 Purchases of investments, net of sales and maturities (2,751) — (2,751) Purchases of property, equipment and capitalized software (1,562) (1,784) 222 Originations and purchases of loans, net of repayments and maturities (1,321) (1,637) 316 Customer funds administered — (25) 25 Other (1,755) (603) (1,152) Total uses of cash (18,038) (14,240) (3,798) Effect of exchange rate changes on cash and cash equivalents (3) 29 (32) Increase in cash and cash equivalents, including cash within businesses held for sale $ 4,101 $ 3,309 $ 792 Less: net increase in cash within businesses held for sale 119 (25) 144 Net increase in cash and cash equivalents $ 4,220 $ 3,284 $ 936 2026 Cash Flows Compared to 2025 Cash Flows Increased cash flows provided by operating activities were driven by increased earnings, timing of government payments, other favorable working capital dynamics and legislative changes from the Inflation Reduction Act impacting pharmacy rebates."},{"id":"e239","location":"June 2026 Form 10-Q, insurance and HMO statutory capital requirements","sourceId":"filing-2","excerpt":"Regulatory Capital. Our regulated insurance and HMO subsidiaries have specified levels of statutory capital required to be maintained, which fluctuates based upon premiums received and the MCR of the regulated subsidiary."},{"id":"e240","location":"June 2026 Form 10-Q, risk-limiting agreements and reduced capital requirements","sourceId":"filing-2","excerpt":"We have various agreements with reinsurers that could limit our risk of loss under certain circumstances, thus reducing our capital and surplus requirements."},{"id":"e242","location":"June 2026 Form 10-Q, investment diversification and partial floating-rate matching","sourceId":"filing-2","excerpt":"We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts."},{"id":"e249","location":"April 2026 proxy, actual 2025 executive equity award mix and terms","sourceId":"filing-3","excerpt":"Hemsley was as follows:\n ​\n ​\n Equity Type \n ​\n ​\n ​\n Equity Mix* \n ​\n ​\n ​\n Details \n ​\n ​\n ​\n ​\n Performance Shares \n ​\n ​\n ​\n 50% \n ​\n ​\n ​\n •\n Pay-for-performance alignment with drivers of shareholder value\n ​\n •\n Weighted equally between three-year cumulative adjusted earnings per share and three-year average return on equity\n ​\n •\n Vesting between 0% and 200% of the target value based upon actual results\n ​\n •\n Performance share payouts are determined formulaically \n ​\n ​\n ​\n ​\n ​\n Non-Qualified Stock Options \n ​\n ​\n ​\n 25% \n ​\n ​\n ​\n •\n Provides incentives for sustained long-term stock price appreciation\n ​\n •\n Only has value if the Company’s stock price increases\n ​\n •\n Typically vest ratably over four years \n ​\n ​\n ​\n ​\n ​\n RSUs \n ​\n ​\n ​\n 25% \n ​\n ​\n ​\n •\n Aligns interests of executives with those of long-term shareholders\n ​\n •\n Provides retentive value and discourages excessive risk-taking for short-term gains\n ​\n •\n Full value shares that typically vest ratably over four years\n ​\n ​\n ​\n ​\n *\n Based on grant date fair value of total stock-based awards\n ​\n ​\n 2026 Proxy Statement 45\n ​\n \n TABLE OF CONTENTS\n ​\n Board of Directors \n ​\n ​\n ​\n Corporate Governance \n ​\n ​\n ​\n Executive Compensation \n ​\n ​\n ​\n Audit \n ​\n ​\n ​\n Annual Meeting \n ​\n ​\n ​\n Other Information\n ​\n Metrics underpinning the 2024-2026, 2025-2027 and 2026-2028 Performance Shares"},{"id":"e263","location":"April 2026 proxy, actual 2023–2025 performance share payout","sourceId":"filing-3","excerpt":"As discussed below, the actual payout for the 2023-2025 performance period is 0%."},{"id":"e278","location":"April 2026 proxy, weaker observed relationship between 2025 performance and reported compensation","sourceId":"filing-3","excerpt":"While a strong correlation between financial performance and any increases in the compensation amounts reported in the SCT existed in measurement periods prior to 2025, a similar correlation between financial performance in 2025 and compensation amounts reported is not as readily apparent."},{"id":"e279","location":"April 2026 proxy, option grant and performance improvement awards explaining compensation divergence","sourceId":"filing-3","excerpt":"This is largely due to Mr. Hemsley’s 2025 stock option grant and the one-time December 2025 Performance Improvement Awards granted to certain NEOs (as described in the “Compensation Discussion and Analysis” section of this proxy statement."},{"id":"e334","location":"April 2026 proxy, 2025 consolidated financial performance","sourceId":"filing-3","excerpt":"​ ​ ​ ​ ​ ​ ​ ​ ​ Our Company ​ ​ Financial Performance ​ ​ ​ ​ Market Cap: $299B ​ ​ ​ Revenue: $447.6B ​ ​ ​ Net Earnings: $12.1B ​ ​ ​ Fully Diluted Earnings Per Share: $13.23 ​ ​ ​ ​ Earnings from Operations: $19.0B ​ ​ ​ Cash Flow from Operations: $19.7B ​ ​ ​ Return on Equity: 12.8% ​ ​ ​ Annual Cash Dividend: $8.84 ​ ​ Our agenda of reform • Mission and Culture."},{"id":"e335","location":"April 2026 proxy, adopted clawbacks, retention and hedging restrictions","sourceId":"filing-3","excerpt":"​ ​ Our Executive Compensation Plan Design is Aligned with our Compensation Program Principles ​ ​ Plan Design ​ ​ ​ Pay for Performance ​ ​ ​ Enhance long-term value ​ ​ ​ Sustained performance ​ ​ ​ Competitive Pay ​ ​ ​ ​ More than 90% of executive compensation is delivered in the form of annual and long-term incentives ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At least 75% of the long-term incentives are in the form of performance-based stock (inclusive of awards delivered in stock options and performance shares) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Performance-based incentives use a balanced set of performance measures, with different metrics used for annual and long-term incentives ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Double-trigger accelerated vesting of stock compensation awards ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Policy to not provide cash severance exceeding 2.99x the sum of base salary and bonus to executives ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ All long-term incentive awards are denominated and settled in stock ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adopted clawback policies for (i) recoupment of incentive compensation in accordance with SEC and NYSE rules, and (ii) recoupment of cash or stock compensation in the event of fraud or misconduct causing material restatement, material detrimental conduct or violation of non-compete, non-solicit or confidentiality provisions ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Insider trading policy prohibits hedging and pledging of shares by directors and executives ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock retention policy generally requires executive officers to hold, for at least one year, one-third of the net shares acquired upon vesting or exercise of any stock compensation award ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 Proxy Statement 3 ​ TABLE OF CONTENTS​​ Alignment of Pay-for-Performance Philosophy and 2025 Incentive Compensation Outcomes Aligning the economic interests of our executives with those of our shareholders through the Company’s pay-for performance philosophy is a fundamental tenet of the Company’s incentive compensation plan design principles."},{"id":"e336","location":"April 2026 proxy, lead independent director authority and executive sessions","sourceId":"filing-3","excerpt":"​ ​ Lead Independent Director role ​ ​ ​ ​ Board Leadership and Meeting Oversight ​ ​ ​ • Preside at all meetings of the Board at which the Chair is not present and at executive sessions of the Board’s Independent Directors ​ • Meet individually with the Chair after each regularly scheduled Board meeting ​ • Call meetings of the independent directors, as appropriate, and, if needed, the entire Board ​ • Approve the agendas and meeting schedules for Board meetings with the Chair ​ • Coordinate the preparation of agendas and materials for executive sessions of the Board’s independent directors ​ ​ ​ ​ ​ Independent Director Coordination ​ ​ ​ • Serve as the principal liaison between the independent directors and the Chair ​ • Facilitate open dialogue among the independent directors during Board meetings, executive sessions and outside of Board meetings ​ • Communicate to the Chair any decisions, suggestions, views, or concerns of the independent directors in executive sessions or outside of Board meetings ​ • Meet periodically with individual independent directors to discuss Board and Committee performance, effectiveness and composition ​ ​ ​ ​ ​ Governance and Board Effectiveness ​ ​ ​ • Assist the Chair of the Governance Committee in reviewing and reporting on the results of Board and Committee performance self-evaluations ​ • Interview, along with the Governance Committee Chair, all Board candidates and make recommendations to the Governance Committee ​ ​ ​ ​ ​ Board Operations and Committee Support ​ ​ ​ • Serve, as needed, as an ex officio member of each Board Committee and assist Board Committee Chairs ​ • Ensure the appropriateness (including quality and quantity) and timeliness of information provided to the Board ​ • Where appropriate, support the Company in interactions with shareholders and regulators in consultation with the Chair ​ ​ ​ Additionally, our independent directors meet in executive session without members of management present at each regular quarterly Board and Committee meeting and when necessary during telephonic meetings."},{"id":"e337","location":"April 2026 proxy, historical 2025 say-on-pay support","sourceId":"filing-3","excerpt":"At the 2025 Annual Meeting, our Say-on-Pay proposal received 60% support."},{"id":"e338","location":"April 2026 proxy, adopted restriction on future front-loaded awards","sourceId":"filing-3","excerpt":"​ ​ The following summarizes feedback received, actions taken in response and their impact: ​ ​ Shareholder Feedback ​ ​ ​ Actions Taken ​ ​ ​ Impact of Action ​ ​ ​ ​ Strong preference for the use of annual stock awards rather than front-loaded awards going forward ​ ​ ​ Adopted a policy to not grant front-loaded awards in the future barring extraordinary circumstances, which we do not foresee at this time."},{"id":"e339","location":"April 2026 proxy, 2025 incentive performance against thresholds","sourceId":"filing-3","excerpt":"The following table sets forth the financial and non-financial performance measures and goals established for 2025, as well as 2025 performance results: ​ ​ 2025 Performance Measure ​ ​ ​ Weighting ​ ​ ​ Threshold Performance ​ ​ ​ Target Performance ​ ​ ​ Maximum Performance ​ ​ ​ 2025 Adjusted Performance ​ ​ ​ ​ Financial Metrics ​ ​ ​ ​ Revenue* ​ ​ ​ 30% ​ ​ ​ $438.6 billion ​ ​ ​ $461.7 billion ​ ​ ​ $484.8 billion ​ ​ ​ Between threshold and target ​ ​ ​ ​ Operating Income* ​ ​ ​ 30% ​ ​ ​ $32.7 billion ​ ​ ​ $38.5 billion ​ ​ ​ $44.3 billion ​ ​ ​ Below threshold ​ ​ ​ ​ Cash Flow from Operations* ​ ​ ​ 15% ​ ​ ​ $27.2 billion ​ ​ ​ $32.0 billion ​ ​ ​ $36.8 billion ​ ​ ​ Below threshold ​ ​ ​ ​ Non-Financial Metrics ​ ​ ​ ​ NPS ​ ​ ​ 12.5% ​ ​ ​ 2025 Performance: Between threshold and target for NPS ​ ​ ​ ​ EXI ​ ​ ​ 12.5% ​ ​ ​ 2025 Performance: Between threshold and target for EXI ​ ​ ​ * 2025 adjusted performance represents the Company’s financial results under the Company’s annual cash incentive plan."},{"id":"e340","location":"April 2026 proxy, incentive-plan adjustment discretion","sourceId":"filing-3","excerpt":"The annual incentive plan allows for adjustments to the Company’s reported results for the impact of changes in accounting principles, extraordinary items and unusual or non-recurring gains or losses, including significant differences from the assumptions contained in the financial plan upon which the incentive targets were established."},{"id":"e341","location":"April 2026 proxy, increased reserves against provider loans and customer balances","sourceId":"filing-3","excerpt":"In the fourth quarter of 2025, the Company increased its reserves for net collection expectations associated with provider loans and other customer balances."},{"id":"e343","location":"March 2026 Form 10-Q, cash and investments including cash available for general corporate use","sourceId":"filing-6","excerpt":"As of March 31, 2026, our cash, cash equivalent, available-for-sale debt securities and marketable equity securities balances of $80.0 billion included approximately $28.0 billion of cash and cash equivalents (of which $1.1 billion was available for general corporate use), $50.1 billion of debt securities and $1.9 billion of investments in marketable equity securities."},{"id":"e344","location":"March 2026 Form 10-Q, revolving facilities and commercial paper support","sourceId":"filing-6","excerpt":"Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes."},{"id":"e364","location":"October 2026 filed earnings release, third-quarter and nine-month operating earnings","sourceId":"filing-7","excerpt":"6,563 4,315 23,544 18,584 Interest expense ..............................................................................................................."},{"id":"e371","location":"October 2026 filed earnings release, third-quarter and nine-month common-shareholder earnings","sourceId":"filing-7","excerpt":"$4,110 $2,348 $15,874 $12,046 Diluted earnings per share attributable to UnitedHealth Group common shareholders (a) ......................................................................................................"},{"id":"e374","location":"October 2026 filed earnings release, diluted weighted-average common shares","sourceId":"filing-7","excerpt":"902 908 906 912 (a) The calculation of diluted earnings per share includes an immaterial reduction to the numerator related to forward share repurchase contracts for the nine months ended September 30, 2026."},{"id":"e384","location":"October 2026 filed earnings release, UnitedHealthcare third-quarter operating results","sourceId":"filing-7","excerpt":"• UnitedHealthcare’s third quarter 2026 earnings from operations were $2.8 billion and operating margin was 3.3% compared to $1.8 billion and 2.1% in the third quarter 2025."},{"id":"e385","location":"October 2026 filed earnings release, management attribution of UnitedHealthcare earnings improvement","sourceId":"filing-7","excerpt":"The year-over-year increase was driven by benefit changes and pricing discipline, combined with medical and operating cost management."},{"id":"e387","location":"October 2026 filed earnings release, third-quarter employer attrition","sourceId":"filing-7","excerpt":"• The number of people served contracted by 165,000 in the third quarter 2026 due to employer attrition."},{"id":"e391","location":"October 2026 filed earnings release, Medicare Advantage contraction since year-end","sourceId":"filing-7","excerpt":"• Seniors served through Medicare Advantage, including programs serving complex populations included in Medicaid, have contracted by 935,000 since year-end 2025."},{"id":"e397","location":"October 2026 filed earnings release, Optum Health revenue decline and insufficient local care presence","sourceId":"filing-7","excerpt":"• Optum Health’s third quarter 2026 revenues of $22.9 billion decreased 10% year-over-year as a result of fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence to sustain its clinicians."},{"id":"e401","location":"October 2026 filed earnings release, Optum Insight third-quarter revenue growth","sourceId":"filing-7","excerpt":"• Optum Insight reported third quarter 2026 revenues of $5.5 billion, an increase of 3% year-over-year."},{"id":"e407","location":"October 2026 filed earnings release, adjusted scripts and customer membership declines","sourceId":"filing-7","excerpt":"Adjusted scripts were 393 million compared to 414 million in the year ago quarter due to membership declines within UnitedHealthcare and other customers."},{"id":"e420","location":"October 2026 filed earnings release cash-flow schedule, share-based compensation row label","sourceId":"filing-7","excerpt":"115 (955) Share-based compensation ..........................................................................................................................................................."},{"id":"e421","location":"October 2026 filed earnings release cash-flow schedule, nine-month share-based compensation values","sourceId":"filing-7","excerpt":"843 795 Loss on sale of subsidiary and subsidiaries held for sale .........................................................................................................."},{"id":"e423","location":"October 2026 filed earnings release cash-flow schedule, operating cash-flow row label","sourceId":"filing-7","excerpt":"4,327 2,777 Cash flows from operating activities .........................................................................................................................................."},{"id":"e424","location":"October 2026 filed earnings release cash-flow schedule, nine-month operating cash-flow values","sourceId":"filing-7","excerpt":"25,087 18,589 Investing Activities (Purchases of investments, net of sales and maturities) sales and maturities of investments, net of purchases ..............."},{"id":"e428","location":"October 2026 filed earnings release, September debt-to-capital ratio","sourceId":"filing-7","excerpt":"• Debt-to-capital ratio was 41.7% as of September 30, 2026, compared to 41.2% in the second quarter 2026."},{"id":"e800","location":"June 2026 meeting-results filing, actual 2026 advisory compensation vote","sourceId":"filing-11","excerpt":"The Company’s executive compensation was approved by a non-binding advisory vote based upon the following votes:\nFor\nAgainst\nAbstain\nBroker \nNon-Votes\n% of Votes For*\n559,434,838\n117,731,618\n1,163,998\n89,736,263\n82.74%\n3.Ratification of the appointment of Deloitte & Touche LLP."},{"id":"e881","location":"February 2026 compensation amendment, adopted holding requirement","sourceId":"filing-13","excerpt":"The amendment adds a two-year share holding requirement following a three-year cliff vesting."},{"id":"e882","location":"February 2026 compensation amendment, CEO net-share holding deadline","sourceId":"filing-13","excerpt":"Specifically, Mr. Hemsley must hold any net shares acquired upon exercise of the stock option until May 14, 2030, except in the event of death or disability."}],"changes":["Retain the qualified narrow verdict: current integrations and extended delivery arrangements support bounded switching friction, without establishing a group-wide cost advantage.","Extend operating evidence through September 2026: nine-month operating earnings were $23.544 billion versus $18.584 billion, and common-shareholder earnings were $15.874 billion versus $12.046 billion. Recovery coexists with employer attrition, lower pharmacy scripts and insufficient local value-based-care density.","Replace the prior missing-capital-headroom limitation with disclosed December 2025 aggregate statutory capital and surplus of $43.1 billion against approximately $23.2 billion necessary to satisfy requirements. These are aggregate statutory amounts, not a disclosed RBC ratio or proof of subsidiary-level fungibility.","Update governance context: actual 2026 say-on-pay support was 82.74%, compared with 60% in 2025. The proxy also explicitly reports an actual 0% payout for the 2023–2025 performance share period.","Retain mixed numerical assessments where warranted; updated earnings and shareholder support do not establish exceptional durability or erase realized operating weaknesses."],"limitations":["The catalog identifies generic competitor categories, without naming competing insurers, pharmacy benefit managers or technology vendors. Competitor arrays are empty; relative market position and cost superiority remain unestablished.","Most evidence consists of issuer filings and operating disclosures. Management explanations of pricing, efficiency, quality and product benefits are distinguished from reported outcomes; they do not independently establish causation or exceptional performance.","Optum Insight backlog includes anticipated renewals and affiliated business. Remaining performance obligations have different scope and exclusions and cannot be treated as a directly comparable backlog update.","Membership and script changes provide indirect retention evidence and include eligibility changes, market exits, product mix and affiliated demand. Customer renewal rates and migration costs are absent.","Current financial assessments use filings dated within 550 days of October 20, 2026. Dates retain their filed classification. The February 2025 filing is older than that window and does not establish current sufficiency.","Latest quantitative statutory capital evidence is for December 2025. Subsidiary-specific solvency ratios, exact RBC denominators, current reserve adequacy studies and risk-transfer counterparty recoverability are absent.","September earnings-release tables are fragmented and unaudited. They establish the cited reported outcomes but do not supply complete updated solvency, distribution, reserve or liquidity detail.","Executive ownership amounts and complete individual realized compensation are absent. Adopted award terms and disclosed payouts support alignment assessment without assuming future vesting."],"qualityAssessments":[{"category":"moat","checks":[{"criterion":"structural_advantage","grade":2,"rationale":"Multiyear delivery and vendor integrations support limited switching friction. Pharmacy network breadth and discounted access demonstrate scale, but comparative costs and network effects are unproven. Insufficient local care presence directly limits a broader scale thesis.","evidenceIds":["e107","e112","e113","e114","e397"]},{"criterion":"durability","grade":2,"rationale":"Extended delivery periods and disclosed remaining performance obligations support persistence. Backlog declined and includes anticipated renewals and affiliated agreements, preventing a strong conclusion about durable external demand.","evidenceIds":["e107","e108","e109","e110","e111","e197"]},{"criterion":"customer_dependency","grade":2,"rationale":"Integration and service duration indirectly support technology customer dependency. Employer attrition and lower scripts across UnitedHealthcare and other customers show that dependency is uneven across the group. No migration-cost or renewal-rate measurement is supplied.","evidenceIds":["e107","e112","e387","e407"]},{"criterion":"erosion_resilience","grade":1,"rationale":"The 2025 pricing failure and operating earnings decline, subsequent membership losses and insufficient local care density demonstrate fragility. September 2026 earnings recovery and Optum Insight revenue growth provide offsets but do not yet establish sustained resistance to erosion.","evidenceIds":["e116","e117","e364","e391","e397","e401"]}]},{"category":"pricing_power","checks":[{"criterion":"realized_pricing","grade":2,"rationale":"First-half revenue benefited from pricing despite fewer people served, and management attributes third-quarter UnitedHealthcare improvement partly to pricing discipline and benefit changes. Material 2025 underpricing and realized pricing-related contraction demonstrate mixed power rather than painless pass-through.","evidenceIds":["e116","e134","e205","e384","e385"]},{"criterion":"retention","grade":1,"rationale":"Benefit and pricing actions caused Medicare Advantage contraction; third-quarter employer attrition and lower pharmacy scripts add realized demand weakness. First-half fee-based membership growth partly offsets this. These are indirect retention indicators, not measured churn, and some contraction reflects eligibility or exits.","evidenceIds":["e205","e234","e387","e391","e407"]},{"criterion":"margin_resilience","grade":2,"rationale":"Operating earnings fell 41% in 2025 before recovering through September 2026. First-half MCR improved to 85.3% from 87.1%, with favorable reserve development, pricing and cost management all contributing. Recovery demonstrates corrective capacity but cannot be attributed solely to pricing.","evidenceIds":["e117","e130","e136","e364","e384","e385"]},{"criterion":"contractual_freedom","grade":1,"rationale":"Annual fixed premiums delay cost pass-through, while government funding and minimum medical loss ratios constrain economics. Benefit, network and supplemental premium adjustments provide some discretion. The voluntary exchange-profit rebate pledge further limits retained pricing benefits.","evidenceIds":["e115","e183","e205","e225","e226"]}]},{"category":"strong_management","checks":[{"criterion":"capital_discipline","grade":2,"rationale":"First-half operating cash generation accompanied $4.813 billion of net debt repayments and reduced cash repurchases; nine-month operating cash flow reached $25.087 billion. Cash timing benefits, subsidiary capital support and unproven acquisition returns temper the assessment.","evidenceIds":["e1","e166","e236","e423","e424"]},{"criterion":"incentive_alignment","grade":2,"rationale":"Actual equity award terms, adopted clawbacks and retention requirements, the CEO holding amendment and a disclosed 0% performance-share payout support alignment. Reported 2025 compensation nevertheless diverged from financial performance because of special awards, and adjustment discretion remains. Ownership amounts are absent.","evidenceIds":["e249","e263","e278","e279","e335","e340","e881","e882"]},{"criterion":"execution","grade":2,"rationale":"2025 operating income and cash flow missed incentive thresholds, and pricing materially underestimated claims costs. Recovery through September 2026 demonstrates corrective execution, but employer attrition, lower scripts and care-density failures remain. Assessment uses operating outcomes; management's causal explanations are qualified.","evidenceIds":["e116","e339","e364","e371","e387","e397","e407"]},{"criterion":"governance","grade":2,"rationale":"Independent-director authority, executive sessions, an adopted front-loaded-award restriction and an unqualified internal-control opinion support functioning oversight. Actual say-on-pay support improved from 60% to 82.74%; this is shareholder approval, not proof of oversight effectiveness. Incentive adjustment discretion and compensation divergence retain material qualifications.","evidenceIds":["e128","e278","e336","e337","e338","e340","e800"]}]}],"financialAssessments":[{"category":"financial_strength","checks":[{"criterion":"capital_adequacy","grade":2,"rationale":"December 2025 estimated aggregate statutory capital and surplus was $43.1 billion against approximately $23.2 billion necessary to satisfy regulatory requirements, supporting a disclosed aggregate cushion. Net capital infusions and agreements reducing requirements qualify that evidence. No RBC ratio is inferred; subsidiary distribution of capital and updated quantitative solvency are absent.","evidenceIds":["e1","e4","e5","e158","e239","e240"]},{"criterion":"liquidity_funding","grade":2,"rationale":"Nine-month operating cash flow of $25.087 billion, first-half net debt repayment, revolving facilities and covenant compliance support funding capacity. March cash available for general corporate use was only $1.1 billion, subsidiary transfers are restricted, and several disclosed rating outlooks were negative. Cash timing benefits and missing facility amounts limit confidence.","evidenceIds":["e122","e154","e216","e236","e343","e344","e423","e424"]},{"criterion":"asset_liability_risk","grade":2,"rationale":"About 90% of medical claims settle within 90 days, and disclosed investment diversification and partial floating-rate matching mitigate some exposures. Favorable reserve development and an immaterial debt-security credit allowance are offsets to elevated claims costs, unrealized investment losses and increased provider-balance reserves. Full reserve adequacy and risk-transfer recoverability remain unestablished.","evidenceIds":["e49","e51","e56","e127","e136","e158","e242","e341"]},{"criterion":"earnings_resilience","grade":2,"rationale":"The company remained profitable through the 2025 operating earnings decline and reported $15.874 billion of common-shareholder earnings for nine months of 2026 versus $12.046 billion. Recovery supports resilience, qualified by reserve-development benefits, medical-cost volatility and 44% CMS premium revenue concentration in 2025.","evidenceIds":["e39","e117","e136","e371"]}]},{"category":"capital_allocation","checks":[{"criterion":"capital_efficiency","grade":2,"rationale":"Reported consolidated ROE was 12.8% in 2025 and annualized first-half 2026 ROE was 24.3%, using common-shareholder earnings over average shareholders' equity. The recovery is meaningful but volatile and partly aided by reserve development. This is a consolidated accounting return, not a statutory insurance-capital return.","evidenceIds":["e130","e132","e136","e334"]},{"criterion":"distributions_and_buffers","grade":2,"rationale":"First-half dividends of $4.092 billion and cash repurchases of $1.646 billion, plus the $2.0 billion forward settlement paid July 1, were below first-half common-shareholder earnings of $11.764 billion. Net debt repayment and the disclosed aggregate statutory cushion support restraint, but subsidiary capital support, transfer restrictions and absent updated subsidiary solvency constrain a stronger assessment.","evidenceIds":["e1","e4","e5","e122","e130","e223","e236"]},{"criterion":"dilution_and_cost","grade":2,"rationale":"Nine-month diluted weighted-average shares declined to 906 million from 912 million, demonstrating net share-count reduction. Nine-month share-based compensation rose to $843 million from $795 million, while 2025 unrecognized compensation remained $1.333 billion. Repurchases and lower first-half interest expense are offsets, but financing costs persist and September debt-to-capital increased to 41.7% from 41.2% in June.","evidenceIds":["e22","e130","e159","e374","e420","e421","e428"]},{"criterion":"investment_discipline","grade":2,"rationale":"First-half cash deployment included $1.562 billion of property, equipment and capitalized software spending, lower acquisition outlays and disposition proceeds. The completed $3.0 billion acquisition includes $1.5 billion payable within one year, with returns unproven. The 2025 Optum Health loss, increased provider-balance reserves and subsequent insufficient local care density demonstrate weaknesses alongside corrective portfolio action.","evidenceIds":["e117","e166","e236","e341","e397"]}]}],"qualityPolicy":"quality-scores-3","sourcePolicy":"issuer-evidence-8","financialAssessmentPolicy":"financial-industry-1","financialSector":"insurance","basisHash":"facc5ffa925584b4322980f127aca79f3d48c933840dc0f0edc16ec581b74b19","updatedAt":"2026-10-20T01:31:20.276Z","sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000062/unh-20251231.htm","publishedAt":"2026-03-02","sha256":"dd2d8292e562fc0fa34ee322b8bad234b889221f989b921d16cfb1bba4121ce9","dateKind":"filed","citationPolicy":"numeric-blocks-2"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000197/unh-20260630.htm","publishedAt":"2026-08-10","sha256":"3cb8935dbdcba65dfb066926b06da09a165b409523e514c8e8b8ea2765998706","dateKind":"filed","citationPolicy":"numeric-blocks-2"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/731766/000110465926046125/tm261387-6_def14a.htm","publishedAt":"2026-04-21","sha256":"3f9831d2547227f1dd1b9ecfea6aa45333bfa4bc2c8e966fcd8f03967cae6a49","dateKind":"filed","citationPolicy":"numeric-blocks-2"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000127/unh-20260331.htm","publishedAt":"2026-05-05","sha256":"52fd7cb8572f32efc71f6dcceeb837decf91e801f055c88fb595810c6b43ea97","dateKind":"filed","citationPolicy":"numeric-blocks-2"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000255/earningsrelease3q26unh.htm","publishedAt":"2026-10-13","sha256":"74ab4c27dc4914d9da10fd8e4f118f4fda6a8eae7fd68a0667f1109a8906d61e","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176625000063/unh-20241231.htm","publishedAt":"2025-02-27","sha256":"41708cd03e28d21212a2949b116ac7ca0fd842741377a3f6bed7cf38ce6f8575","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000255/uhgearnings_q32026vfinal.htm","publishedAt":"2026-10-13","sha256":"341bc8e6144ed5a321696f9597f56c6efb1bc961971fa1fbac27a06c9190d25a","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-9","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000191/earningsrelease2q26_7152.htm","publishedAt":"2026-07-16","sha256":"9e13c7c5d012a9e518c34f11169515702e8080582e9e7617c587dbef491787b1","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-10","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000191/uhgearnings_q22026vpower.htm","publishedAt":"2026-07-16","sha256":"10bf281fc3d409bc1d1cfca9ecdf396a06639a6ff6020c8e9a61d8f178767c07","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-11","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000138/unh-20260601.htm","publishedAt":"2026-06-05","sha256":"7438ba7c001072b23376c96ba69b5e0d7614ed1bc48b1317134b82ac1bd96deb","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-12","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000064/unh-20260224.htm","publishedAt":"2026-03-02","sha256":"f5d2c6206426791c764adc4b14b06d075e44cd3c45ce6584c387e07d4fa9d83d","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-13","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000046/unh-20260223.htm","publishedAt":"2026-02-25","sha256":"aa7c635413360693c4d51a9322d995e40c76a8c1f3240d5ea8881f6ac5ef0c37","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-14","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176625000314/unh-20251118.htm","publishedAt":"2025-11-21","sha256":"f4a4d6aba80efbbd79ed82f2b77b7d3a83cdf6ea8d1ed52e7f01e11e32040cc6","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-15","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176625000310/unh-20251106.htm","publishedAt":"2025-11-13","sha256":"acaf9afcf4e070a40b43c06849b1809caf8066bcfa16b6b9bc99cba187713ab1","citationPolicy":"numeric-blocks-2","dateKind":"filed"}],"model":"gpt-6.1-sol","providerId":"codex:2607d474e19929267a5ae3c3fc1de16bda08ad35074644b4d9c5a0b1652fb17b","usage":{"input_tokens":88530,"cached_input_tokens":21120,"cache_write_input_tokens":0,"output_tokens":6173,"reasoning_output_tokens":152}},"signals":[{"period":"2021","end":"2021-12-31","values":{"gross_margin":89.209205937475,"operating_margin":8.33457928977006,"roic":null,"fcf_margin":6.9155797869936055,"sbc_revenue":0.27816701843204206},"issues":{"pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_sales":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","ev_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roce":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roiic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","net_debt_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","interest_coverage":"Not applicable to banks and insurers: these ratios use an industrial-company capital model."}},{"period":"2022","end":"2022-12-31","values":{"gross_margin":89.60303798717925,"operating_margin":8.771848643579446,"roic":null,"fcf_margin":7.219846866690112,"sbc_revenue":0.2853511515847015},"issues":{"pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_sales":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","ev_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roce":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roiic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","net_debt_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","interest_coverage":"Not applicable to banks and insurers: these ratios use an industrial-company capital model."}},{"period":"2023","end":"2023-12-31","values":{"gross_margin":89.56735607687382,"operating_margin":8.707234770815505,"roic":null,"fcf_margin":6.910785690836388,"sbc_revenue":0.28496698257907227},"issues":{"pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_sales":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","ev_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roce":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roiic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","net_debt_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","interest_coverage":"Not applicable to banks and insurers: these ratios use an industrial-company capital model."}},{"period":"2024","end":"2024-12-31","values":{"gross_margin":88.33460744782377,"operating_margin":8.06614402989922,"roic":null,"fcf_margin":5.172655004771683,"sbc_revenue":0.2543232453444856},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_sales":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","ev_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roce":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roiic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","net_debt_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","interest_coverage":"Not applicable to banks and insurers: these ratios use an industrial-company capital model."}},{"period":"2025","end":"2025-12-31","values":{"gross_margin":88.68214144474459,"operating_margin":4.237130977038075,"roic":null,"fcf_margin":3.5916410280471975,"sbc_revenue":0.21695075821050255},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pb":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","ev_sales":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","ev_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","ebitda_margin":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roce":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roiic":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","roe":"The reported inputs required for this metric are unavailable in the extracted statements for this period.","roic_wacc":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","net_debt_ebitda":"Not applicable to banks and insurers: these ratios use an industrial-company capital model.","interest_coverage":"Not applicable to banks and insurers: these ratios use an industrial-company capital model."}}],"sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000062/unh-20251231.htm","publishedAt":"2026-03-02","sha256":"dd2d8292e562fc0fa34ee322b8bad234b889221f989b921d16cfb1bba4121ce9","dateKind":"filed","citationPolicy":"numeric-blocks-2"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000197/unh-20260630.htm","publishedAt":"2026-08-10","sha256":"3cb8935dbdcba65dfb066926b06da09a165b409523e514c8e8b8ea2765998706","dateKind":"filed","citationPolicy":"numeric-blocks-2"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/731766/000110465926046125/tm261387-6_def14a.htm","publishedAt":"2026-04-21","sha256":"3f9831d2547227f1dd1b9ecfea6aa45333bfa4bc2c8e966fcd8f03967cae6a49","dateKind":"filed","citationPolicy":"numeric-blocks-2"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000127/unh-20260331.htm","publishedAt":"2026-05-05","sha256":"52fd7cb8572f32efc71f6dcceeb837decf91e801f055c88fb595810c6b43ea97","dateKind":"filed","citationPolicy":"numeric-blocks-2"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000255/earningsrelease3q26unh.htm","publishedAt":"2026-10-13","sha256":"74ab4c27dc4914d9da10fd8e4f118f4fda6a8eae7fd68a0667f1109a8906d61e","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176625000063/unh-20241231.htm","publishedAt":"2025-02-27","sha256":"41708cd03e28d21212a2949b116ac7ca0fd842741377a3f6bed7cf38ce6f8575","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000255/uhgearnings_q32026vfinal.htm","publishedAt":"2026-10-13","sha256":"341bc8e6144ed5a321696f9597f56c6efb1bc961971fa1fbac27a06c9190d25a","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-9","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000191/earningsrelease2q26_7152.htm","publishedAt":"2026-07-16","sha256":"9e13c7c5d012a9e518c34f11169515702e8080582e9e7617c587dbef491787b1","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-10","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000191/uhgearnings_q22026vpower.htm","publishedAt":"2026-07-16","sha256":"10bf281fc3d409bc1d1cfca9ecdf396a06639a6ff6020c8e9a61d8f178767c07","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-11","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000138/unh-20260601.htm","publishedAt":"2026-06-05","sha256":"7438ba7c001072b23376c96ba69b5e0d7614ed1bc48b1317134b82ac1bd96deb","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-12","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000064/unh-20260224.htm","publishedAt":"2026-03-02","sha256":"f5d2c6206426791c764adc4b14b06d075e44cd3c45ce6584c387e07d4fa9d83d","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-13","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176626000046/unh-20260223.htm","publishedAt":"2026-02-25","sha256":"aa7c635413360693c4d51a9322d995e40c76a8c1f3240d5ea8881f6ac5ef0c37","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-14","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176625000314/unh-20251118.htm","publishedAt":"2025-11-21","sha256":"f4a4d6aba80efbbd79ed82f2b77b7d3a83cdf6ea8d1ed52e7f01e11e32040cc6","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-15","url":"https://www.sec.gov/Archives/edgar/data/731766/000073176625000310/unh-20251106.htm","publishedAt":"2025-11-13","sha256":"acaf9afcf4e070a40b43c06849b1809caf8066bcfa16b6b9bc99cba187713ab1","citationPolicy":"numeric-blocks-2","dateKind":"filed"}],"history":[{"version":11,"updatedAt":"2026-10-29T11:18:10.916Z","verdict":"narrow","value":null},{"version":10,"updatedAt":"2026-10-27T23:59:08.795Z","verdict":"narrow","value":null},{"version":9,"updatedAt":"2026-10-24T20:17:12.088Z","verdict":"narrow","value":null},{"version":8,"updatedAt":"2026-10-23T09:00:23.028Z","verdict":"narrow","value":null},{"version":7,"updatedAt":"2026-10-22T19:55:13.023Z","verdict":"narrow","value":null},{"version":6,"updatedAt":"2026-10-19T22:04:21.334Z","verdict":"narrow","value":null},{"version":5,"updatedAt":"2026-10-19T13:57:15.039Z","verdict":"narrow","value":null},{"version":4,"updatedAt":"2026-10-18T16:49:32.080Z","verdict":"narrow","value":null},{"version":3,"updatedAt":"2026-10-18T16:35:43.872Z","verdict":"narrow","value":null},{"version":2,"updatedAt":"2026-10-18T02:27:49.793Z","verdict":"narrow","value":null}],"hasRequested":false,"requestStatus":"completed","researchIssue":null,"archivedMoat":null,"scope":"supported_catalog"}